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ABSTRACT
To assess the use of different medications in CMD patients with 
and without medication. 111 CMDs with dissociation and 36 CMDs 
individuals without dissociation were assessed comprehensively 
using history of signs and symptoms, muscle and joint palpation 
and history of chief complaint and proper criteria for CMD and bru-
xism. The Dissociative Experience Scale (DES) and questionnaires 
were used to gather information about the level of dissociation and 
different medication use. 100% of those individuals with CMDs 
+ dissociation, CMDs-Dissociation and controls had a history of 
previous use of medication. The experimental and control groups 
did not differ in the frequency of history of medication, however, 
the amount of reported medication was greater in the group with 
CMD and dissociation (Kruskal-Wallis test p=0,02). There was a po-
sitive and significant association between the degree of dissocia-
tion and the amount of medication use in the CMD + Dissociation 
group. The CMDs + Dissociation, CMD-Dissociation and the control 
groups used a variety of medications, the amount of analgesics/
anti-inflammatory drugs, muscle relaxants, anti-anxiety and antide-
pressants drugs was greater in the CMD + dissociation group. The 
amount of antidepressants used by the CMDs + Dissociation group 
was greater and significant (p=0.02). A positive and significant cor-
relation was observed in the amount of medication use and scores 
in dissociation in the CMDs + dissociation group (Pearson r=0.006). 
Many CMDs individuals present significant scores in dissociation, 
thus, a comprehensive evaluation of such patients is mandatory.
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RESUMO
Avaliar o uso de medicamentos diferentes em pacientes com 
Distúrbios Craniomandibulares com e sem dissociação. 111 
indivíduos com Distúrbios Craniomandibulares + dissociação, 36 
com Distúrbios craniomandibulares sem dissociação e 16 controles 
foram avaliados de forma completa usando história dos sinais e 
sintomas, palpação muscular e articular, e história da queixa principal 
e critérios para Distúrbios Craniomandibulares e bruxismo. A Escala 
de Experiências Dissociativas (DES) e questionários foram usados 
para obter informação sobre o grau de dissociação e medicação. 
100% dos indivíduos com Distúrbios craniomandibulares + 
Dissociação, Distúrbios craniomandibulares e Sem Dissociação 
e Controles tinham uma história de uso de medicação. Os grupos 
experimentais e controle não foram diferentes na frequência do uso 
de vários tipos de medicação; entretanto, a quantidade de medicação 
relatada foi maior no grupo Distúrbios craniomandibulares + 
Dissociação (Teste Kruskal-Wallis, p=0.02). Houve associação 
positiva e significante entre grau de dissociação e a quantidade de 
medicação usada no grupo Distúrbios Craniomandibulares com 
Dissociação. Observou-se uma correlação positiva e significante 
entre grau de dissociação e quantidade de medicação usada no 
grupo Distúrbios craniomandibulares com Dissociação (p<0.006). 
Os grupos Distúrbios craniomandibulares + Dissociação, 
Distúrbios craniomandibulares- Dissociação e controle tinham 
história de uso de muitos medicamentos diferentes, a quantidade 
de analgésicos/antiinflamatórios, relaxantes musculares, 
ansiolíticos e antidepressivos usada foi maior no grupo Distúrbios 
craniomandibulares com Dissociação. Muitos indivíduos com 
Distúrbios craniomandibulares apresentam valores significantes 
em dissociação, sendo necessária uma avaliação completa .
Palavras-Chave
Distúrbios Craniomandibulares, Dissociação, Medicação, Bruxismo.
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1 INTRODUCTION AND REVIEW
1.1 Pain and craniomandibular disorders
Pain is recognized as being more an experience than a sensation and it has a sensory dimension 
that registers the nature of the initiating stimulus, including its quality, intensity, location and duration1. 
Pain is undoubtedly the most common condition seen in primary care and the most costly one as 
well, and musculoskeletal disorders occur very frequently2. Multiple pains are usually associated with 
psychiatric disturbances through somatization and other mechanisms, unfavorable health appraisal, 
psychiatric impairment, increased severity and persistence of pain and disability3. Craniomandibular 
Disorders (CMDs) are common conditions affecting up to 33% of the population. They are characterized 
by unilateral or bilateral pain and internal derangements in the temporomandibular joints (ID-TMJs) 
and/or in the craniofacial muscles4. Patients who later develop chronic CMDs appear to have more 
psychosocial distress before the diagnosis of duration than do individuals who have acute symptoms 
that later subside5.
Jaw pain may be associated with bruxism (BB) at daytime and/or during sleep and it may be 
worse in the night when patients are having posttraumatic (PTSD) nightmares. Some headaches may 
also occur and/or can be aggravated by stress-related muscular bracing in the neck and shoulder2. The 
complex nature of CMDs and orofacial pain (OFP), requires a multidisciplinary approach. CMDs and 
OFP patients are more effectively treated in an interdisciplinary setting at a single facility with dental 
and medical specialists or by a multidisciplinary team whose members, working in different facilities, 
coordinate both diagnosis and treatment1.
1.2 Dissociation
Dissociation refers to an alteration of the normal integration of experience and is defined in terms 
of its role disrupting the usually integrated functions of consciousness, memory, identity or perception 
of the environment6. It is considered as a defense against the painful presence of unwanted psychic 
elements, or as an attempt to rid the mind of them by forcibly eliminating some aspects of the expe-
rience7. A dissociative disorder (DID) is characterized by the presence of two or more distinct identities, 
or personality states, that recurrently take control over an individual´s behavior accompanied by an 
inability to recall important personal information8. It has been proposed that dissociation is a continuum 
of increasingly large amounts of dissociated ego which ranges from transient psychogenic amnesia to 
fugue states and depersonalization to partial DID to fully developed DID.
DID has been correlated with somatization and the typical signs and symptoms of somatization 
occurring together with dissociation are unusual pain tolerance, headaches which come on suddenly 
in the midst of a therapy hour and difficulties to respond to psychopharmacological treatment6. Clinical 
studies have identified that 12-30% of psychiatric inpatients have DID and approximately 3-5% would 
be diagnosed with dissociation8. One study10 evaluated patients in a mental health center and found 
that 39/151 (25.8%) of them presented with DID, the mean Dissociative Experience Scale (DES) score 
in such group was about 34.6 and there was a close association between conversion and dissociation. 
Studies showed that the median score of 17 DID patients was 40.7, the median originally reported in 
another study was 57.06 in 20 MPD subjects and 4.9 in normal subjects11.
1.3 Medication use and dissociation
Patients with DID symptoms present many disorders in the musculoskeletal system, including 
myofascial pain (MPD) and headaches of muscular origin. Severe headache is the most common symp-
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tom in DID individuals12, most headaches are vascular, tension-type or a combination of both, and they 
are usually worst during personality changes12.
Many DID patients may have used a wide range of medication trials including major and minor 
tranquilizers, benzodiazepines for severe anxiety and antidepressants with a consistently poor respon-
se, before comprehensive assessment13. Multiple biomedical treatments including a variety of drugs in 
patients with multiple pains, somatization and other psychiatric disorders may be incomplete at best3. 
Such a limited approach in patients with multiple pains, including CMDs may perpetuate an unsatis-
fying search for pharmacological symptom management3. Because in some studies, CMDs and more 
severe BB have been associated with hysteria and multiple complaints14 and it is common knowledge 
that dissociation is associated with a hysterical personality and somatization15, it is expected that DID 
patients use analgesics, anti-anxiety and antidepressant drugs more frequently as compared to non 
DID controls. Because there is no available information in medication use in CMD patients with and 
without dissociation, the objectives of this study is threefold:
1. Assess the frequency of medication use in CMD individuals and controls;
2. Evaluate the use of different medications in those CMD s individuals with, without dissocia-
tion and controls;
3. Test the hypothesis that the amount of different medications is increased in individuals with 
CMD and Dissociation as compared to those with CMD and no dissociation and control subjects.
2 MATERIAL AND METHODS
Data for this research were gathered retrospectively by examining the charts of 147 CMDs and 
bruxing behavior individuals with headaches, referred consecutively to a Center for the Study of CMD, 
Orofacial Pain and Oral Jaw Habits to UNIRG University Center in the years 2011-2014. Each evaluated 
chart contained accurate data about CMDs signs and symptoms, the most common headache types 
and BB classified as mild, moderate, severe, and extreme according to the number of signs and symp-
toms. Information about tenderness to palpation, types and description of pain including pain severity 
using the Visual Analogue Scale (VAS) in the masticatory system, description of myofascial pain (MPD), 
types and characteristics of specific internal derangements of the temporomandibular joint (TMJ-ID), 
characteristics and type of headaches and/or facial pain including duration, frequency and intensity, 
were also recorded in every chart. Patients were classified as presenting CMDs if they demonstrated 
specific signs/symptoms, including a complaint of pain in the masticatory muscles, noises in the TMJs, 
difficulties to perform lateral and/or opening jaw movements, tenderness in the masticatory muscles 
during palpation and headaches usually of muscular origin. Patients were classified as presenting CMDs 
and BB according to criteria published previously14. Only those charts presenting clear, sufficient and 
accurate information defining the most common types of headache pain were reviewed and included 
in the study. Accurate information about medication use including analgesics and anti-inflammatory 
drugs, anti-anxiety, antidepressants, muscle relaxant and other types of drugs was also collected from 
the 111 charts in CMD and dissociative patients, from 36 CMDs no dissociative patients and from 16 
non CMD controls. All patients in this study presented signs and symptoms of CMDs + BB according 
to criteria accepted in the literature on CMD and BB, published previously elsewere16.
In order to have information about DID in CMDs and BB individuals, the Dissociative Experience 
Scale (DES), which is a 28-item self- reported instrument developed by Bernstein and Putnam17, was 
filled out by all individuals presenting CMD and BB. Such a scale is not a diagnostic tool, but it may be 
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used as a screening instrument for chronic DIDs. A cut- off score of 30 has been shown to be useful in 
screening DIDs among general psychiatric patients18. However, noteworthy of mention is that different 
levels of dissociation do exist in different individuals. Based on the scores observed in every chart, tho-
se individuals presenting 0-10 were considered as presenting CMD without dissociation (Group CMD 
without dissociation n=36), those presenting scores of 11 or above were considered as presenting CMD 
with dissociation (CMD and dissociation group n=111). Controls were those referred in the same period 
of time, presenting with a complaint in the stomatognathic system, but without the characteristics of 
CMDs. Because every patient referred to the dental school signs an informed consent giving permission 
to use their material for research purposes, this investigation was approved by the Ethical Committee 
of the Dental School (003-2015).
Inclusion Criteria to allocate individuals in the groups presenting CMDs and Dissociation, and 
CMD and no Dissociation:
1. Three or more signs and symptoms of CMDs
2. Presence of mild, moderate, severe or extreme bruxism
3. A signed consent to participate in the study
4. Having fulfilled completely the Dissociative Scale of Bernstein and Putnam
5. Seeking active treatment for facial pain, bruxism and or headache pain.
6. Stringent and accepted criteria from the literature for CMDs, BB, and various headache types.
Exclusion criteria to allocate individuals to the experimental groups
1. No signs and symptoms of CMDs and BB;
2. Presence of neurological disorders;
3. Presence of severe psychiatric disturbances;
4. Not seeking active treatment for CMDs and headaches;
5. Cognitive impairment to respond to the questionnaires including the DES.
Controls (N=16) were those individuals without the characteristics of CMDs, but presenting with a 
complaint in one or more components of the masticatory system. Most of them were not seeking active 
treatment for pain and some of their complaints were excessive tooth wear, tenderness to palpation, 
ear stuffiness and/ or cervical pain.
Statistical analysis: Tests deemed appropriate for this study included the Fisher ´ exact test, Kruskal-
Wallis non parametric test, Pearson Product Moment Correlation Test and Spearman rho (non parametric) 
to test the correlation between number of medications used and scores in DID in different groups.
3 RESULTS
Table 1 presents demographic data and shows that the mean ages in the CMD with dissociation, 
CMD without dissociation and control groups were about 35.0 (SD=11.0, Range 14—73), 38.0 (SD=12.2, 
Range=18-75) and 39.6 (SD=12.0, Range 23-63) years, respectively. The frequencies of females in such 
groups were 91%, 91.7% and 75%, respectively. Table 2 shows that the history of previous or current 
medication use in the CMD + Dissociation, CMD without dissociation and controls groups was 100%. 
Table 3 provides information about the frequencies of analgesics and/or anti-inflammatory drugs, mus-
cle relaxants, anti-anxiety, antidepressants and “other medications” reported by patients and controls. 
Analgesics/anti-inflammatory drugs were used in 85.6%, 83.3% and 100% in the CMD + Dissociation, 
CMD - Dissociation and control groups respectively (Fisher´s exact test, p=0.78, p=0.21 and p=0.16: non 
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significant differences when comparing pairs of groups). Muscle relaxants were used in 56.7%, 55.5% and 
43.8% respectively, in the same groups (Fisher´s exact tests p=1.00, p=0.42 and p=0.55: non significant 
differences when comparing pairs of groups). Anti-anxiety drugs were used by 23.4%, 13.8% and 12.5% 
of those presenting CMD and dissociation, CMD without dissociation and control group, respectively 
(Fisher´exact tests p=0.25, p=0.52 and p=1.00: non significant differences when comparing pairs of 
groups). Antidepressants´ use was reported in 41.4%, 25% and 25% in the same groups, respectively 
(Fisher´s exact tests p=0.11, p=0.27, and p=1.00, non significant differences when comparing pairs of 
groups). Finally, use of “other drugs” was reported in 13.5% , 19.4% and 6.3% respectively in the same 
groups (Fisher´s exact tests p=0.42, p=0.69, and p=0.40=non significant differences when comparing 
pairs of groups). Regarding the total amount of drugs, Table 4 shows medians of 4.90, 3.94% and 3.87, 
reported by the groups presenting CMD + DID, CMD non DID and controls, respectively (Kruskal-Wallis 
non parametric test p=0.02, a significant difference in history of total amount of medication use). Table 
5 depicts data about the relationship between amount of medication use and scores in DID in those 
presenting CMDs + DID (Pearson Rho=0.25, p=0.006), CMDs Non DID (Pearson Rho=0.18, p=0.27) and 
Controls (Pearson Rho= -0.009, p=0.97). Thus, there was a positive and significant relationship between 
higher scores in dissociation and increased amount of medication in the CMD + DID group.
Table 1 - Demographic data in 111 patients with CMDs+ DID, 36 CMD- DID and 16 control individuals.
CMDs +DID
N=111
CMDs-DID
N=36
Controls
N=16
n % n % n %
GENRE
Females 101 91.0 33 91.7 12 75
Males 10 9.0 3 8.3 4 25
TOTALS 111 100 36 100 16 100
Mean Age 35.0 38.0 39.6
SD 11.0 12.2 12.0
Range 14-73 18-75 23-63
Table 2 - Frequency of medication use in patients with CMDs + DID, CMDs-DID, and controls.
CMDs+DID
N=111
CMDs-DID
N=36
Controls
N=16
n % n % n %
With history of drugs use 111 100 36 100 16 100
Without history of drugs use 0 0 0 0 0 0
TOTALS 111 100 36 100 16 100
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Table 3 - Frequency of specific medication use in patients with CMDs+ DID, CMDs-DID and controls.
Drug type
CMDs+DID
N=111
CMDs-DID
N=36
Controls
N=16
n % n % n %
Analgesic/anti-inflammatory 95 85.6 30 83.3 16 100*
Amount 304/111=2.7 85/36=2.3 40/16=2.5
Muscle relaxants 63 56.7 20 55.5 7 43.8**
Amount 112/111=1.09 28/36=0.77 9/16=0.56
Anti-anxiety 26 23.4 5 13.8 2 12.5***
Amount 34/111=0.30 7/36=0.19 2/16=0.13
Antidepressants
46 41.4 9 25 4 25.0****
72/111=0.65 13/36=0.36 4/16=0.25
Others 15 13.5 7 0.19 1 6.3*****
Amount 17/111= 0.15 8/36=0.22 1/16=0.06
*Fisher´s exact test CMDs + DID versus CMDs no DID= p=0.78; CMDs + DID versus Controls p=0.21; CMDs no DID versus Controls p=0.16.
**Fisher´s exact test CMDs + DID versus CMDs no DID p=1.00; CMDs + DID versus Controls p= 0.42; CMDs no DID versus Controls p=0.55
***Fisher´ s exact test CMDs + DID versus CMDs no DID, p=0.25; CMDs + DID versus Controls, p=0.52; and CMDs no DID versus Controls, p=1.00.
****Fisher´s exact test CMDs + DID versus CMDs no DID, p=0.11; CMDs + DID versus Controls, p=0.27; CMDs no DID versus Controls, p=1.00.
*****Fisher´ s exact test CMDs + DID versus CMDs no DID, p=0.42; CMDs + DID versus Controls, p=0.69; and CMDs no DID versus Controls, p=0.40.
Table 4 - Amount of medication used in the CMDs + DID, CMDs no DID and control groups  
(All drugs included in every patient).
GROUPS
CMDs+DID
N=111
CMDs-DID
N=36
Controls
N-16
Mean 4.90 3.94 3.87*
SD 2.7 2.72 2.91
Range 0----14 0---12 1-14
Kruskal-Wallis non parametric test p=0.02. The use of different medications increased 
from the control to the CMDs-DID and to the CMDs+DID groups.
Dunn´s multiple comparison test:
CMDs + Dissociation versus CMDs-Dissociation p>0.05
CMDs-Dissociation versus controls p>0.05
CMDs-Dissociation versus controls p>0.05
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Table 5 - Pearson product moment correlation coefficients between dissociation and amount of me-
dication in individuals with DID, without DID and controls.
GROUPS
CMDs + DID*
N=111
CMDs –DID*
N=36
Controls**
N=16
Pearson Rho 0.256 0.18 -0.009
P value 0.006 0.27 0.97
Significant? Yes No No
*Statistical test used: Pearson Rho (Parametric)    **Statistical test used: Spearman Rho (Non parametric)
4 DISCUSSION
Frequency of medication use in CMDs with, without DID and control individuals.
One goal of this study was to assess a possible difference in medication use in the CMDs + DID, 
CMD-No DID and control groups. We found that medication was used very frequently but in different 
amounts in the aforementioned groups. Even though the control group presented no characteristics 
of CMDs, they have used analgesics/anti-inflammatory, muscle relaxants and anti-anxiety drugs very 
frequently, probably because they presented some complaint of pain, joint noises, cervical pain and 
ear complaints. The very frequent use of medications in the CMDs groups with or without DID can be 
explained by the fact that most patients in such groups presented headaches, cervical, facial and or 
TMJ pain and some of them also demonstrated high levels of anxiety, depression and somatization. It 
is very likely that such a frequent use of medication in the CMDs groups may have been related to the 
presence of pain in different anatomic sites and higher scores in anxiety, depression and somatization. 
On the other hand, frequent, but lesser amounts of medication in the control group may have been related 
with the presence of more local pains and/or other complaints mostly of musculoskeletal character.
CMD patients with/ without dissociation usually have pain in single and multiple sites including 
headaches, anxiety, depression and somatization, which explains the need of frequent use of different 
medications. Some CMDs patients may present chronic pain and a tendency to manifest an interior 
conflict through physical symptoms19. Additionally, it has been reported that headaches are a dynamic 
condition and regular follow up is needed for adjustments in medication and to reinforce pharmaco-
logical and nonpharmacological modalities of therapy20. CMDs patients in this study had used many 
different drug types to alleviate pain, anxiety and or depression. Additionally, if patients are not satisfied 
with treatment results, they may try additional medications, thus increasing the variety, duration and 
amount of medication they use. In this regard and noteworthy of mention is that headaches may wor-
sen at times, particularly during stressful events or at times of interpersonal conflicts, thus increasing 
medication use20.
In one study in CMDs individuals14, researchers reported higher scores in hysteria and greater 
number of painful sites with the severity of BB. Because hysteria is closely related with both somati-
zation and with DID in many CMDs individuals, such disorders may increase the need for medication 
use in many CMDs patients. Such assumption is in line with one investigation21, indicating that DID 
is a chronic disease of many symptoms that occurs in the context of overwhelming experiences in 
childhood. Because of the myriad of signs and symptoms present in such patients, they may use a 
variety of medications, very frequently. Poor compliance with the use of medication and with clinicians´ 
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instructions may also increase the shift to other medications in CMDs patients, thus, further increasing 
the frequency of their use. Following this line of reasoning, one review of the literature20 reported that 
less than 50% of headache patients complied with proper use of medication and more than 10% never 
filled their initial prescription.
Approximately 75% of headache patients expressed negative or ambivalent attitudes toward 
medication use because of potential short or long term side effects20. Poor compliance and inadequate 
medication use may lead to treatment failures, recurrence of symptoms, and use of greater amounts of 
different medications in CMDs patients. Furthermore, ongoing research indicates that medication does 
not work well for people with DID, results are unpredictable, having little or no effect and unintended 
exaggerated effects. In other cases, medications may work in the beginning, but soon cease having any 
therapeutic effect22. In most cases of chronic headaches, daily opioids fail to provide sustained relief 
or reduce functional impairment. Frequent opioid use is likely to contribute to central sensitization and 
progressive worsening of the headache through multiple mechanisms23.
Frequency of different medication use in those with, without dissociation and control individuals.
A second objective of this investigation was to assess the use of different medications in the 
groups with and without DID and controls. In the current study, most patients in the CMDs groups and 
control one reported the use of analgesics and anti-inflammatory drugs (Fisher´s exact test p=0.78, 
p=0.21, and p=0.16, showing that the differences in the use of such drugs were not significant). Such 
high frequency of analgesics use was expected as analgesic overuse often accompanies the treatment 
for headaches which are common in patients with DID, a disorder occurring very frequently in those 
individuals presenting with substance abuse8. In the current study, CMDs with DID used analgesics 
more frequently than CMDs without DID. Although a positive trend was observed, the difference did not 
reach significance.
We also found that 56.7%, 55.5% and 43.8% individuals in the CMD + DID, CMD no DID and Controls 
reported the use of muscle relaxants (Fisher´ s exact tests p=1.00, p=0.42, and p=0.55, respectively), 
demonstrating no significant differences in muscle relaxants use when comparing such groups. Because 
muscle relaxants were used very frequently in these three subgroups of CMD patients with and without 
DID and in the control group, the outcome of the current study has partial support in one investigation24, 
asserting that centrally acting muscle relaxants are frequently used in the treatment of craniomandibular 
disorders. Flexeril or cyclobenzaprine hypochloride, which is chemically similar to antidepressants, is 
the drug of choice for generalized muscle pain24. In fact, patients and controls in this study reported 
the use of Miosan (Cyclobenzaprine), Tandrilax and Torsilax (Brazilian brand names), very frequently.
In the current study, 23.4%, 13.8% and 12.5% patients in the CMD + DID, CMD - DID and control 
groups, respectively, reported the use of anti-anxiety drugs, but the difference was not significant when 
pairs of groups were compared (Fisher´s exact tests p=0.25, p=0.52, and p=1.00, respectively). CMDs 
and DID individuals in the current study demonstrated a higher frequency in the use of anti-anxiety 
drugs. This is not surprising, as benzodiazepines have been the most successful agents used to calm 
thought processes and decrease switching in dissociative patients and alprazolan is the most com-
monly used agent in that group25.
41.4% , 25%, and 25% of the CMD + DID, CMD - DID and Controls reported the use of antidepres-
sants. The group presenting CMDs + DID demonstrated higher frequency of antidepressant use (41.4%) 
when compared with the CMD no Dissociation group and the difference almost reached significance 
(Fisher´s exact test p=0.11). This frequency of antidepressant use was much lower as compared to 
the frequency of 62.1% of antidepressant use reported in a previous investigation25. However, patients 
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in such a study demonstrated higher scores in dissociation, thus probably presenting higher scores in 
depression and somatization as well, indicating increasing need of antidepressant use.
When CMDs with and without DID groups were pooled together, the frequency of reported anti-
depressant use was about 37.4%, frequency, which was very similar to the prevalence of 40.8% of anti-
depressant use reported in a previous study26. Because severe and or extreme bruxism with CMDs are 
viewed as those presenting with more intense pain, higher scores in anxiety, depression, somatization 
and hysteria, and in the current study, those with CMDs and DID demonstrated higher scores in antide-
pressants use, the results of this investigation is partially confirmed by a previous study26, demonstrating 
that the frequency of antidepressants use increased with the severity of both CMDs and BB.
When comparing the use of “other drugs”, their frequency was lower in the three groups and dif-
ferences did not reach significance. The greater use of “other drugs” in the CMDs with and without DID 
probably indicates higher scores in somatization and other psychiatric disorders, but such assumption 
needs further validation and scrutiny.
Because there were not statistical significant differences in the frequency of medication use in the 
aforementioned groups, studies looking at the amount, frequency, type and duration of medication use 
in similar groups would be more fruitful as compared to investigations merely examining the frequency 
of medication use. It may be that when proper diagnosis is not carried out and inadequate treatment 
is instituted, the complaints become more chronic, pain occurs more frequently, is more intense, and 
encourage clinicians and /or patients to look for additional and “more effective medications”, thus in-
creasing the use of different ones. Supporting in part this point of view, one study20 defends the notion 
that in patients with headaches, somatization and other psychological disorders, the older stepped-care 
approach, starting with the simple analgesics in every headache sufferer regardless of disability and 
advancing the use of such drugs as needed, based on patient satisfaction with treatment, may cause 
unnecessary suffering and be detrimental to the patient´s collaboration with treatment.
It may also be that in most cases, patients are initially treated as if analgesics were the only 
therapeutic approach necessary to alleviate their signs and symptoms, and also as if other disorders 
were not present concomitantly, and at the same time ignoring the presence of psychological disor-
ders including anxiety, depression, somatization and anger-in. This line of evidence is supported in 
part by one study24, indicating that anti-anxiety medication may be prescribed as supportive therapy 
in cases where high levels of stress and anxiety are associated with CMDs. For instance, diazepan can 
be prescribed for acute exacerbations of masticatory muscle pain, sleep disorders and BB. Additional 
and strong support for this line of evidence comes from one research1, indicating that in some patients 
an occlusal splint may not be the only mode of treatment presenting limited effectiveness. If so, such 
patients may be referred to further treatment with psychotherapy and antidepressants use.
Because in many patients with headaches and psychiatric co-morbidities the Hamilton Rating 
Scale for anxiety and depression may be high in the most common headache types20, it would be more 
appropriate to use a combination of therapy including anti-anxiety, antidepressants, occlusal splints and 
analgesics, rather than using an approach based on the older stepped-care management with analgesics.
Amount of medication use in those with CMD and dissociation, CMD without dissociation and 
controls.
In the current investigation, it was found that the amount of analgesics used in the groups with 
CMDs + DID, CMD - DID and controls was more or less equivalent. The amount of muscle relaxants 
that was reported by such groups decreased from the CMD + DID group to the CMD- DID group and the 
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amount of anti-anxiety drugs reported by patients in such groups decreased from the CMD group with 
DID to the control one. Finally, the amount of antidepressants reported by the same groups decreased 
from the group with CMD + DID to the group without DID and to the control one. Because greater amou-
nts of anti-anxiety and antidepressant drugs were used in the CMDs groups with and without DID, such 
findings indicate that such groups present higher scores in anxiety, depression and muscle tension and 
or/that they are more unstable psychologically.
This line of reasoning is in accordance with one study1, indicating that a variety of psychological 
factors play a role predisposing, perpetuating and/or maintaining a pain disorder. Personality, emotional 
and attitudinal characteristics of CMDs individuals can be interpreted as psychological predisposing 
factors. Higher levels of somatization disorders occurring frequently in those patients with CMDs and 
DID and in those with headaches, possibly due to heightened vigilance to bodily sensations, may am-
plify pain20, thus they may use greater amounts of analgesics, anti-anxiety and antidepressant drugs. 
Substance abuse occurs very frequently in 33% of dissociative patients8.
Because medication overuse is a common finding in patients with CMDs and/or headaches, 
pharmacological and behavioral treatment may show significant benefit following drug withdrawal 
in patients with medication overuse headaches27 and/or in those with CMDs signs and symptoms. 
Depression is a common disorder in DID patients and they are more likely to use antidepressants to 
alleviate their suffering28. CMDs and DID patients in the current study used greater amounts of anti-
depressants and one study reported that it is not rare to find DID patients suffering from depression 
and confusional states. Such patients may fail to respond to any kind of drug treatment and may shift 
from one drug to the other to alleviate pain, tension, anxiety and depression29. Patients with refractory 
head, neck and facial pains presenting with daily or nearly daily headaches may use larger amounts of 
multiple medications,23 including antidepressants and anti-anxiety drugs. CMDs patients with DID in 
the current study, used greater amounts of anti-anxiety and antidepressant drugs. It may be that such 
patients do not respond to conventional drugs and they may present with intense anxiety and affective 
symptoms21. If so, they may also shift to drugs that alleviate and/or are more effective for their intense 
affective disorders.
To the extent of our knowledge, this is the first study in the literature assessing medication use 
in patients with CMDs and BB with or without DID. Because flaws are inherent in most studies in this 
field, the results herein presented should be replicated in other studies using similar methods so as to 
increase their validity and reliability.
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